Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.
Apoquel
IL-31
JAK
chewable
dog
film-coated tablet
oclacitinib maleate
onset of action
pruritus
Journal
Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
Titre abrégé: J Vet Pharmacol Ther
Pays: England
ID NLM: 7910920
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
15
04
2022
received:
21
01
2022
accepted:
03
05
2022
pubmed:
20
5
2022
medline:
14
7
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
Oclacitinib maleate (Apoquel®, Zoetis Inc.) is commonly used around the world for the control/treatment of pruritus associated with allergic dermatitis and the control/treatment of atopic dermatitis in dogs at least 12 months of age. A new flavored chewable formulation of oclacitinib has been developed where more than 90% of doses offered to dogs were freely accepted when tested in clinical trials. The objective of this study was to determine whether the new chewable formulation of oclacitinib has a similar onset of anti-pruritic activity as the original oclacitinib film-coated tablets (FCT). Twenty-one laboratory beagle dogs were randomized to treatment and received placebo, 0.4-0.6 mg/kg oclacitinib FCT or 0.4-0.6 mg/kg flavored chewable oclacitinib tablet (n = 7/group). Efficacy was measured by assessing reduction in pruritus 1-3 h post-administration of treatments. Pruritus was induced by injecting canine IL-31, intravenously (2.5 μg/kg), approximately 15 min prior to the pruritus observation window. Results from this study demonstrated both oclacitinib FCT and the flavored chewable oclacitinib tablet significantly reduced IL-31-induced pruritus within 1-3 h post-dosing compared to placebo (p = .0069 and .0113, respectively), suggesting the new formulation of oclacitinib chewable tablets works as quickly to reduce pruritus in dogs as the oclacitinib FCT.
Substances chimiques
Dermatologic Agents
0
Maleates
0
Pyrimidines
0
Sulfonamides
0
oclacitinib
99GS5XTB51
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-384Subventions
Organisme : Zoetis
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Aleo, M., Ross, S., Becskei, C., Coscarelli, E., King, V., Darling, M., & Lorenz, J. (2018). Palatability testing of oral chewables in veterinary medicine for dogs. Open journal for Veterinary Medicine, 8, 107-118.
Collard, W. T., Hummel, B. D., Fielder, A. F., King, V. L., Boucher, J. F., Mullins, M. A., Malpas, P. B., & Stegemann, M. R. (2014). The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. Journal of Veterinary Pharmacology and Therapeutics, 37, 279-285.
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Martin, D. D., Walsh, K. F., Harfst, J. A., Follis, S. L., King, V. L., Boucher, J. F., & Stegemann, M. R. (2013). Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary Dermatology, 24, 479-e114.
Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JKS, Stegemann MR A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel [R]) in client-owned dogs with atopic dermatitis. Veterinary Dermatology 2013; 24:587-597, e141-582.
Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR Efficacy of oclacitinib (Apoquel[R]) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Veterinary Dermatology 2014;25:512-518, e586.
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton-Fry, M. (2014). Oclacitinib (APOQUEL([R])) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics, 37, 317-324.
Gonzales, A. J., Fleck, T. J., Humphrey, W. R., Galvan, B. A., Aleo, M. M., Mahabir, S. P., Tena, J. K., Greenwood, K. G., & McCall, R. B. (2016). IL-31-induced pruritus in dogs: A novel experimental model to evaluate anti-pruritic effects of canine therapeutics. Veterinary Dermatology, 27, 34-e10.
Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA, Teel JF, Bammert GF, Dunham SA, Fuller TE, McCall RB Interleukin-31: Its role in canine pruritus and naturally occurring canine atopic dermatitis. Veterinary Dermatology 2013;24:48-53 e11-42.
Olivry, T., DeBoer, D. J., Favrot, C., et al. (2015). Treatment of canine atopic dermatitis: 2015 updated guidelines from the international committee on allergic diseases of animals (ICADA). BMC Veterinary Research, 11, 210.
Thombre, A. G. (2004). Oral delivery of medications to companion animals: Palatability considerations. Advanced Drug Delivery Reviews, 56, 1399-1413.
Visser, V., Walsh, K., King, V., Sture, G., Caneva, L. (2022). Acceptance of Oclactinib maleate (Apoquel®) chewable tablet in client-owned dogs with allergic and atopic dermatitis. BMC Veterinary Research;18:103.